- On March 31, 2026, William Blair upgraded 10x Genomics from “Market Perform” to “Outperform,” citing its best-in-class genomics technology and improving execution.
- The upgrade highlighted a multinational Xenium-based spatial transcriptomics initiative targeting up to 100,000 patient tissue samples, underscoring 10x Genomics’ role in supplying AI-scale biological datasets.
- Next, we’ll examine how this AI-focused spatial data initiative may reshape 10x Genomics’ investment narrative and long-term growth drivers.
Uncover the next big thing with 33 elite penny stocks that balance risk and reward.
10x Genomics Investment Narrative Recap
To own 10x Genomics, you need to believe that its single cell and spatial platforms can become essential infrastructure for high throughput, AI ready biology. William Blair’s upgrade, tied to a 100,000 sample Xenium initiative, reinforces that thesis and supports the near term catalyst of broader spatial adoption. It does not, however, remove the key risk that softer research funding and pricing pressure could still weigh on revenue stability and delay a path to profitability.
Among recent announcements, the PharosAI collaboration stands out as most connected to this AI scale spatial narrative. PharosAI is using Xenium to build multimodal cancer datasets for early diagnosis and precision therapies, in partnership with the UK government and NHS groups. Together with the newly highlighted 100,000 sample effort, it strengthens the case that large, AI driven consortia could become a meaningful driver of recurring consumables demand across Xenium and related platforms.
Yet against these AI data opportunities, investors should also be aware of how shrinking pricing power and heavier discounting of instruments could...
Read the full narrative on 10x Genomics (it's free!)
10x Genomics’ narrative projects $709.8 million revenue and $110.2 million earnings by 2029. This requires 3.4% yearly revenue growth and a $153.7 million earnings increase from -$43.5 million today.
Uncover how 10x Genomics' forecasts yield a $20.14 fair value, a 10% downside to its current price.
Exploring Other Perspectives
Some of the most optimistic analysts were already assuming revenue could reach about US$784.3 million and earnings of roughly US$111.5 million by 2028, which is a far more bullish view than consensus and sits in sharp contrast to worries about revenue instability and rising competition; after William Blair’s upgrade and the 100,000 sample Xenium push, it will be important to see how, or if, those optimistic and cautious narratives shift.
Explore 4 other fair value estimates on 10x Genomics - why the stock might be worth 42% less than the current price!
Form Your Own Verdict
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your 10x Genomics research is our analysis highlighting 2 key rewards and 2 important warning signs that could impact your investment decision.
- Our free 10x Genomics research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate 10x Genomics' overall financial health at a glance.
Want Some Alternatives?
Opportunities like this don't last. These are today's most promising picks. Check them out now:
- The future of work is here. Discover the 33 top robotics and automation stocks leading the charge in AI-driven automation and industrial transformation.
- Capitalize on the AI infrastructure supercycle with our selection of the 36 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- AI is about to change healthcare. These 36 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com